Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons

Journal of the National Cancer Institute

Volumn 103, Issue 2, 2011, Pages 92-104

  Dick, Andrew W ^a   Sorbero, Melony S ^a   Ahrendt, Gretchen M ^b   Hayman, James A ^c   Gold, Heather T ^d   Schiffhauer, Linda ^e   Stark, Azadeh ^f   Griggs, Jennifer J ^g  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PATIENT PREFERENCE; PRIORITY JOURNAL; RADIOTHERAPY; RECURRENCE RISK; STATISTICAL ANALYSIS; SURGEON; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE EFFECTIVENESS RESEARCH; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MASTECTOMY; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; ODDS RATIO; PHYSICIAN'S ROLE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79251476513     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq499     Document Type: Article

References (31)

1. Initial National Priorities for Comparative Effectiveness Research.Washington, DC: National Academies Press 2009.
2. Morrow M, Harris J. Ductal carcinoma in situ and microinvasive carcinoma. In: Harris J, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams and Wilkins; 2010:349-362.
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intra-ductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993-2000. (Pubitemid 29271743)
4. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(3):335-347.
5. Katz SJ, Lantz PM, Janz NK, et al. Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol. 2005;23(13):3001-3007.
6. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst. 2009;101(19):1337-1347.
7. Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009 302(14) 1551-1556.
8. Waljee JF, Hu ES, Newman LA, Alderman AK. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008;15(5):1297-1303.
9. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95-102.
10. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400-418. (Pubitemid 32762083)
11. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381-3387.
12. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247-1252.
13. Carlson RW, Goldstein LJ, Gradishar WJ, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology. 1996;10(11 suppl):47-75.
14. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V.1 2009.Ft Washington, PA: National Comprehensive Cancer Network 2009.
15. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319-5324.
16. Gold HT, Dick AW. Variations in treatment for ductal carcinoma in situ in elderly women. Med Care. 2004;42(3):267-275.
17. Warren JL, Weaver DL, Bocklage T, et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer. 2005;104(9):1840-1848.
18. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6): 443-448.
19. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic fndings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86(3):429-438.
20. Rakovitch E, Pignol JP, Hanna W, et al. Signifcance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007;25(35):5591-5596.
21. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lump-ectomy. J Natl Cancer Inst. 2003;95(22):1692-1702.
22. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specifc survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys. 2005;63(5):1514-1521.
23. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental beneft of larger margins. Am J Surg. 2005;190(4):521-525.
24. Hiotis K, Ye W, Sposto R, Skinner KA. Predictors of breast conservation therapy: size is not all that matters. Cancer. 2005;103(5):892-899.
25. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27(10):1615-1620.
26. Hawley ST, Hofer TP, Janz NK, et al. Correlates of between-surgeon variation in breast cancer treatments. Med Care. 2006;44(7):609-616.
27. Taghian A, Mohiuddin M, Jagsi R, Goldberg S, Ceilley E, Powell S. Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg. 2005;241(4):629-639.
28. Diagnosis and Management of Ductal Carcinoma in Situ (DCIS). Bethesda, MD: National Institutes of Health State-of-the-Science Conference Statement 2009.
29. Hadley J, Mandelblatt JS, Mitchell JM, Weeks JC, Guadagnoli E, Hwang YT. Medicare breast surgery fees and treatment received by older women with localized breast cancer. Health Serv Res. 2003;38(2):553-573.
30. Bickell NA, LePar F, Wang JJ, Leventhal H. Lost opportunities: physicians' reasons and disparities in breast cancer treatment. J Clin Oncol. 2007;25(18):2516-2521.
31. Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys. 2005;61(2):365-373.